Latest & greatest articles for liraglutide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on liraglutide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on liraglutide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for liraglutide

61. [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V]

[Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V] Insulin degludec/liraglutid (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V] Insulin degludec/liraglutid (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment (...) according to §35a Social Code Book V] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Insulin degludec/liraglutid (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V. [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und

2016 Health Technology Assessment (HTA) Database.

62. [Insulin degludec/liraglutide (Addendum to Commission A15-15)]

[Insulin degludec/liraglutide (Addendum to Commission A15-15)] Insulin degludec/liraglutid (addendum zum Auftrag A15-15) [Insulin degludec/liraglutide (Addendum to Commission A15-15)] Insulin degludec/liraglutid (addendum zum Auftrag A15-15) [Insulin degludec/liraglutide (Addendum to Commission A15-15)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation IQWiG. Insulin degludec/liraglutid (addendum zum Auftrag A15-15). [Insulin degludec/liraglutide (Addendum to Commission A15-15)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 327. 2015 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Hypoglycemic Agents; Insulin, Long-Acting Language Published German Country of organisation Germany English summary There is no English language summary available

2016 Health Technology Assessment (HTA) Database.

63. Liraglutide (Saxenda) and obesity: there are still no satisfactory weight loss drugs

Liraglutide (Saxenda) and obesity: there are still no satisfactory weight loss drugs Prescrire IN ENGLISH - Spotlight ''Liraglutide (Saxenda°) and obesity: there are still no satisfactory weight loss drugs'', 1 January 2016 {1} {1} {1} | | > > > Liraglutide (Saxenda°) and obesity: there are still no satisfactory weight loss drugs Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |  (...)  |   |  Spotlight Liraglutide (Saxenda°) and obesity: there are still no satisfactory weight loss drugs FEATURED REVIEW On average, daily liraglutide injections for one year help patients lose only a few kilograms compared with placebo, and weight is gradually regained after treatment discontinuation. Patients who are overweight or obese should not be exposed to the frequent gastrointestinal disorders and the risk of pancreatitis associated with long-term, high-dose liraglutide

2016 Prescrire

64. Liraglutide: Weighing the evidence for weight loss?

Liraglutide: Weighing the evidence for weight loss? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,400 family physicians, family medicine residents and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca August 15, 2016 (...) Liraglutide: Weighing the evidence for weight loss? Clinical Question: Does liraglutide reduce weight and improve health in obese patients? Bottom-line: Once daily Liraglutide 3.0 mg injections reduce weight 3.4%-4.6 % over one year and one in 3-4 patients treated will get a 5% weight loss over placebo. Adverse events (like nausea and vomiting) will cause one in 17 to stop liraglutide. The effect was not sustained beyond drug cessation and long-term health effects in obese non-diabetics are unknown

2016 Tools for Practice

65. Insulin degludec/liraglutide (Xultophy®)

Insulin degludec/liraglutide (Xultophy®) Insulin degludec/liraglutide (Xultophy®) Insulin degludec/liraglutide (Xultophy®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Insulin degludec/liraglutide (Xultophy®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC (...) ), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2544. 2015 Authors' conclusions Insulin degludec/liraglutide (Xultophy®) is recommended as an option for restricted use within NHS Wales. Insulin degludec/liraglutide (Xultophy®) is licensed for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a glucagon-like peptide

2015 Health Technology Assessment (HTA) Database.

66. Insulin degludec/liraglutide (Xultophy) - for the treatment of adults with type 2 diabetes mellitus

Insulin degludec/liraglutide (Xultophy) - for the treatment of adults with type 2 diabetes mellitus Final Appraisal Recommendation Advice No: 2715 – October 2015 Insulin degludec/liraglutide (Xultophy ® ? ) 100 units/3.6 mg per ml solution for injection Submission by Novo Nordisk Ltd Additional note(s): • Insulin degludec/liraglutide (Xultophy ® ? ) should be prescribed by brand name to avoid medication errors. In reaching the above recommendation AWMSG has taken account of the appraisal (...) . Recommendation of AWMSG Insulin degludec/liraglutide (Xultophy ® ? ) is recommended as an option for restricted use within NHS Wales. Insulin degludec/liraglutide (Xultophy ® ? ) is licensed for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a glucagon-like peptide protein-1 (GLP-1) receptor agonist or basal insulin do not provide adequate glycaemic control. Insulin degludec

2015 All Wales Medicines Strategy Group

67. Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)

Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Insulin degludec/Liraglutid – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 July 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A15-15 (...) Insulin degludec/liraglutide – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A15-15 Version 1.0 Insulin degludec/liraglutide – Benefit assessment acc. to §35a SGB V 30 July 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Insulin degludec/liraglutide – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

68. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial Full Text available with Trip Pro

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial To confirm the superiority, compared with placebo, of adding liraglutide to pre-existing basal insulin analogue ± metformin in adults with inadequately controlled type 2 diabetes [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)].In this 26-week, double-blind, parallel-group study, conducted in clinics (...) or hospitals, 451 subjects were randomized 1 : 1 to once-daily liraglutide 1.8 mg (dose escalated from 0.6 and 1.2 mg/day, respectively, for 1 week each; n = 226) or placebo (n = 225) added to their pre-existing basal insulin analogue (≥20 U/day) ± metformin (≥1500 mg/day). After randomization, insulin adjustments above the pre-study dose were not allowed. The primary endpoint was HbA1c change.After 26 weeks, HbA1c decreased more with liraglutide [-1.3% (-14.2 mmol/mol)] than with placebo [-0.1% (-1.2 mmol

2015 EvidenceUpdates Controlled trial quality: predicted high

69. Liraglutide in Weight Management. Full Text available with Trip Pro

Liraglutide in Weight Management. 26510030 2015 10 30 2018 12 02 1533-4406 373 18 2015 10 29 The New England journal of medicine N. Engl. J. Med. Liraglutide in Weight Management. 1779-80 10.1056/NEJMc1509759 Mauvais-Jarvis Franck F eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 89750-14-1 Glucagon-Like Peptide 1 AIM IM N Engl J Med. 2015 Jul 2;373(1):11-22 26132939 N Engl J Med. 2015 Oct 29;373(18):1781-2 26510028 Female Glucagon-Like Peptide 1 analogs

2015 NEJM

70. Liraglutide in Weight Management. Full Text available with Trip Pro

Liraglutide in Weight Management. 26510031 2015 10 30 2018 12 02 1533-4406 373 18 2015 10 29 The New England journal of medicine N. Engl. J. Med. Liraglutide in Weight Management. 1780 10.1056/NEJMc1509759 Gardner David M DM Murphy Andrea L AL eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 89750-14-1 Glucagon-Like Peptide 1 AIM IM N Engl J Med. 2015 Jul 2;373(1):11-22 26132939 N Engl J Med. 2015 Oct 29;373(18):1781-2 26510028 Female Glucagon-Like Peptide 1

2015 NEJM

71. Liraglutide in Weight Management. Full Text available with Trip Pro

Liraglutide in Weight Management. 26510032 2015 10 30 2018 12 02 1533-4406 373 18 2015 10 29 The New England journal of medicine N. Engl. J. Med. Liraglutide in Weight Management. 1780-1 10.1056/NEJMc1509759 Freemark Michael M eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 89750-14-1 Glucagon-Like Peptide 1 AIM IM N Engl J Med. 2015 Jul 2;373(1):82-3 26132945 N Engl J Med. 2015 Oct 29;373(18):1782 26516641 Female Glucagon-Like Peptide 1 analogs

2015 NEJM

72. Liraglutide in Weight Management. Full Text available with Trip Pro

Liraglutide in Weight Management. 26510033 2015 10 30 2018 12 02 1533-4406 373 18 2015 10 29 The New England journal of medicine N. Engl. J. Med. Liraglutide in Weight Management. 1781 10.1056/NEJMc1509759 Paton David M DM eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 89750-14-1 Glucagon-Like Peptide 1 AIM IM N Engl J Med. 2015 Jul 2;373(1):82-3 26132945 N Engl J Med. 2015 Oct 29;373(18):1782 26516641 Female Glucagon-Like Peptide 1 analogs & derivatives

2015 NEJM

73. Liraglutide in Weight Management. (Abstract)

Liraglutide in Weight Management. 26510028 2015 10 30 2018 12 02 1533-4406 373 18 2015 10 29 The New England journal of medicine N. Engl. J. Med. Liraglutide in Weight Management. 1781-2 10.1056/NEJMc1509759 Pi-Sunyer Xavier X SCALE Obesity and Prediabetes Investigators eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 89750-14-1 Glucagon-Like Peptide 1 AIM IM N Engl J Med. 2015 Jul 2;373(1):11-22 26132939 N Engl J Med. 2015 Oct 29;373(18):1779 26510029 N

2015 NEJM

74. Liraglutide in Weight Management. Full Text available with Trip Pro

Liraglutide in Weight Management. 26510029 2015 10 30 2018 12 02 1533-4406 373 18 2015 10 29 The New England journal of medicine N. Engl. J. Med. Liraglutide in Weight Management. 1779 10.1056/NEJMc1509759 Taylor Peter N PN Baglioni Piero P eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 89750-14-1 Glucagon-Like Peptide 1 AIM IM N Engl J Med. 2015 Jul 2;373(1):11-22 26132939 N Engl J Med. 2015 Oct 29;373(18):1781-2 26510028 Female Glucagon-Like Peptide 1

2015 NEJM

75. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study Full Text available with Trip Pro

Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study To examine the efficacy and safety of once-weekly dulaglutide monotherapy (0.75 mg) compared with placebo and once-daily liraglutide (0.9 mg) in Japanese patients with type 2 diabetes.This was a phase III, 52-week (26-week primary endpoint), randomized, double-blind, placebo-controlled (...) , open-label comparator (liraglutide) trial comparing 492 Japanese patients with type 2 diabetes (dulaglutide, n = 281; liraglutide, n = 141; and placebo, n = 70) who were aged ≥20 years. Patients and investigators were blinded to treatment assignment for dulaglutide and placebo but not for liraglutide. The primary objective evaluated the superiority of dulaglutide versus placebo on change from baseline in glycated haemoglobin (HbA1c) at 26 weeks. Analyses were performed on the full analysis set.At

2015 EvidenceUpdates Controlled trial quality: predicted high

76. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. Full Text available with Trip Pro

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. Weight loss of 5% to 10% can improve type 2 diabetes and related comorbidities. Few safe, effective weight-management drugs are currently available.To investigate efficacy and safety of liraglutide vs placebo for weight management in adults with overweight or obesity and type 2 diabetes.Fifty-six-week randomized (2:1:1), double-blind, placebo-controlled, parallel-group (...) trial with 12-week observational off-drug follow-up period. The study was conducted at 126 sites in 9 countries between June 2011 and January 2013. Of 1361 participants assessed for eligibility, 846 were randomized. Inclusion criteria were body mass index of 27.0 or greater, age 18 years or older, taking 0 to 3 oral hypoglycemic agents (metformin, thiazolidinedione, sulfonylurea) with stable body weight, and glycated hemoglobin level 7.0% to 10.0%.Once-daily, subcutaneous liraglutide (3.0 mg) (n

2015 JAMA Controlled trial quality: predicted high

77. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. Full Text available with Trip Pro

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously.We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had (...) a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification. The coprimary end points were the change in body weight and the proportions

2015 NEJM Controlled trial quality: predicted high

78. Liraglutide (Saxenda) for weight loss in non-diabetic obese adults

Liraglutide (Saxenda) for weight loss in non-diabetic obese adults Liraglutide (Saxenda) for weight loss in non-diabetic obese adults Liraglutide (Saxenda) for weight loss in non-diabetic obese adults HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Liraglutide (Saxenda) for weight loss in non-diabetic obese adults. Lansdale: HAYES, Inc (...) .. Healthcare Technology Brief Publication. 2015 Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Adult; Anti-Obesity Agents; Humans; Liraglutide; Obesity; Weight Loss Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo

2015 Health Technology Assessment (HTA) Database.

79. Randomised controlled trial: Subcutaneous liraglutide reduces weight and improves metabolic control in obese participants

Randomised controlled trial: Subcutaneous liraglutide reduces weight and improves metabolic control in obese participants Subcutaneous liraglutide reduces weight and improves metabolic control in obese participants | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Subcutaneous liraglutide reduces weight and improves metabolic control in obese participants Article Text Therapeutics/Prevention Randomised controlled trial Subcutaneous

2015 Evidence-Based Medicine

80. Type 2 diabetes: insulin degludec/liraglutide (Xultophy)

Type 2 diabetes: insulin degludec/liraglutide (Xultophy) T T ype 2 diabetes: insulin degludec/lir ype 2 diabetes: insulin degludec/liraglutide aglutide (Xultoph (Xultophy) y) Evidence summary Published: 3 July 2015 nice.org.uk/guidance/esnm60 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in July 2015. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up (...) - to-date information. Summary In people who are insulin-naïve, insulin degludec/liraglutide (Xultophy) was non-inferior to insulin degludec alone and superior to liraglutide alone for reductions in HbA1c (with a difference of 0.64% compared with liraglutide). In people previously treated with basal insulin, insulin degludec/ liraglutide was superior to insulin degludec alone for reducing HbA1c with a difference of 1.1%. The safety profile and long-term safety concerns of insulin degludec/liraglutide

2015 National Institute for Health and Clinical Excellence - Advice